Visa Launches Stablecoin Platform to Provide Stablecoin Services to Over 2 Billion Merchants
BlockBeats News, July 16th. According to
Visa settles about $150 trillion in payments annually and has already processed stablecoin settlements in the billions of dollars. This platform will integrate Visa's existing stablecoin services, reduce the complexity of clients dealing with blockchain technology, and allow them to focus on the payment experience. Merchants using stablecoins can achieve real-time settlements and lower transaction costs.
The platform will use the stablecoin OUSD, launched by Open Standard two weeks ago, as the strategic starting point for infrastructure, while complementing Visa's support for USDC and USDG. Visa is a partner of Open Standard, and American Express and Mastercard are also involved in OUSD-related partnerships.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
